Claire E Myers

Years Active: 2020-2021
Publications (10 Years): 2

U.S. Food and Drug Administration

University of Pennsylvania (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

U.S. Food and Drug Administration Mar 01 2018

United States

Nonclinical Reviewer :: Office of Oncologic Diseases / Division of Hematology Oncology Toxicology

Education History

University of Pennsylvania

United States

PHD :: Immunology

Publications

Luckson N Mathieu, Erin Larkins, Oladimeji Akinboro, Pourab Roy, Anup K Amatya, Mallorie H Fiero, Pallavi S Mishra-Kalyani, Whitney S Helms, Claire E Myers, Amy M Skinner, Stephanie Aungst, Runyan Jin, Hong Zhao, Huiming Xia, Jeanne Fourie Zirkelbach, Youwei Bi, Yangbing Li, Jiang Liu, Manuela Grimstein, Xinyuan Zhang, Stacie Woods, Kelie Reece, Abdelrahmman M Abukhdeir, Soma Ghosh, Reena Philip, Shenghui Tang, Kirsten B Goldberg, Richard Pazdur, Julia A Beaver, Harpreet Singh
FDA Approval Summary: Capmatinib and Tepotinib for the Treatment of Metastatic NSCLC Harboring MET Exon 14 Skipping Mutations or Alterations. Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Leigh Marcus, Martha Donoghue, Stephanie Aungst, Claire E Myers, Whitney S Helms, Guoxiang Shen, Hong Zhao, Olen Stephens, Patricia Keegan, Richard Pazdur
FDA Approval Summary: Entrectinib for the Treatment of NTRK gene Fusion Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 27 (4) (2020)

Claire E Myers.css-eqlu8i{font-size:small;padding-left:4px;}